{
  "source": "PA-Med-Nec-SSB-Anticonvulsants.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2017-20\nProgram Prior Authorization/Medical Necessity - Single Source Brand\nAnticonvulsants\nMedication/Therapeutic Single Source Brand Anticonvulsants –\nClass Aptiom® (eslicarbazepine), Briviact® (brivaracetam), Epidiolex®\n(cannabidiol), Fintepla® (fenfluramine), Xcopri® (cenobamate) and\nZtalmy® (ganaxolone)\nP&T Approval Date 2/2014, 5/2014, 11/2014, 11/2015, 6/2016, 6/2017, 9/2018, 11/2018,\n11/2019, 7/2020, 10/2020, 10/2021, 1/2022, 5/2022, 10/2022, 11/2022,\n10/2023, 10/2024, 4/2025\nEffective Date 7/1/2025\n1. Background:\nThis program requires a member to try at least one antiepileptic medication prior to\nreceiving coverage for Briviact and at least two antiepileptic medications prior to\nreceiving coverage for Aptiom, Fintepla, Xcopri, and Ztalmy or for Epidiolex when it is\nused for seizures associated with Lennox-Gastaut syndrome. Epidiolex for seizures\nassociated with Dravet syndrome or tuberous sclerosis complex do not require a trial of\nalternative antiepileptic medications.\n2. Coverage Criteriaa:\nA. Aptiom, Xcopri or Ztalmy will be approved based on one of the following:\n1. All of the following:\na. One of the following:\n(1) For Aptiom or Xcopri: diagnosis of partial-onset seizures\n(2) For Ztalmy: diagnosis of seizures associated with cyclin-dependent kinase-\nlike 5 (CDKL5) deficiency disorder confirmed with genetic testing\n-AND-\nb. History of greater than or equal to 8 week trialb of at least two of the following\n(any release formulation qualifies):\n(1) Carbamazepine (e.g. generic Tegretol)\n(2) Divalproex (e.g. generic Depakote)\n(3) Gabapentin (e.g. generic Neurontin)\n(4) Lamotrigine (e.g. generic Lamictal)\n(5) Levetiracetam (e.g. generic Keppra)\n(6) Oxcarbazepine (e.g. generic Trileptal)\n(7) Phenytoin (e.g. generic Dilantin)\n(8) Pregabalin (e.g. generic Lyrica)\n(9) Topiramate (e.g. generic Topamax)\n© 2025 UnitedHealthcare Services Inc.\n1\n(10) Valproic acid (e.g. generic Depakene)\n(11) Z",
    ") Phenytoin (e.g. generic Dilantin)\n(8) Pregabalin (e.g. generic Lyrica)\n(9) Topiramate (e.g. generic Topamax)\n© 2025 UnitedHealthcare Services Inc.\n1\n(10) Valproic acid (e.g. generic Depakene)\n(11) Zonisamide (generic Zonegran)\n-AND-\nc. One of the following:\n(1) Both of the following:\n(a) Documented history of persisting seizures after titration to the highest\ntolerated dose with each medication trial\n(b) Lack of compliance as a reason for treatment failure has been ruled\nout\n-OR-\n(2) Both of the following:\n(a) Documentation of failure due to intolerable side effects.\n(b) Reasonable efforts were made to minimize the side effect (e.g. change\ntiming of dosing, divide dose out for more frequent but smaller doses,\netc.)\n-OR-\n2. For continuation of prior therapy for a seizure disorder\nAuthorization will be issued for 12 months.\nB. Briviact will be approved based on one of the following:\n1. All of the following:\na. Diagnosis of partial-onset seizures\n-AND-\nb. History of greater than or equal to 8 week trialb of at least one of the following\n(any release formulation qualifies):\n(1) Carbamazepine (e.g. generic Tegretol)\n(2) Divalproex (e.g. generic Depakote)\n(3) Gabapentin (e.g. generic Neurontin)\n(4) Lamotrigine (e.g. generic Lamictal)\n(5) Levetiracetam (e.g. generic Keppra)\n(6) Oxcarbazepine (e.g. generic Trileptal)\n(7) Phenytoin (e.g. generic Dilantin)\n(8) Pregabalin (e.g. generic Lyrica)\n(9) Topiramate (e.g. generic Topamax)\n(10) Valproic acid (e.g. generic Depakene)\n© 2025 UnitedHealthcare Services Inc.\n2\n(11) Zonisamide (generic Zonegran)\n-AND-\nc. One of the following:\n(1) Both of the following:\n(a) Documented history of persisting seizures after titration to the highest\ntolerated dose with each medication trial\n(b) Lack of compliance as a reason for treatment failure has been ruled\nout\n-OR-\n(2) Both of the following:\n(a) Documentation of failure due to intolerable side effects.\n(b) Reasonable efforts were made to minimize the side effect (e.g. change\ntiming of dosin",
    "s been ruled\nout\n-OR-\n(2) Both of the following:\n(a) Documentation of failure due to intolerable side effects.\n(b) Reasonable efforts were made to minimize the side effect (e.g. change\ntiming of dosing, divide dose out for more frequent but smaller doses,\netc.)\n-OR-\n2. For continuation of prior therapy for a seizure disorder\nAuthorization will be issued for 12 months.\nC. Epidiolex will be approved based on one of the following:\n1. Diagnosis of seizures associated with Dravet syndrome or tuberous sclerosis\ncomplex\n-OR-\n2. All of the following:\na. Diagnosis of seizures associated with Lennox-Gastaut syndrome\n-AND-\nb. History of greater than or equal to 8 week trialb of at least two generic\nanticonvulsants (e.g. divalproex, lamotrigine, topiramate, valproic acid)\n-AND-\nc. One of the following:\n(1) Both of the following:\n(a) Documented history of persisting seizures after titration to the highest\n© 2025 UnitedHealthcare Services Inc.\n3\ntolerated dose with each medication trial\n(b) Lack of compliance as a reason for treatment failure has been ruled\nout\n-OR-\n(2) Both of the following:\n(a) Documentation of failure due to intolerable side effects.\n(b) Reasonable efforts were made to minimize the side effect (e.g. change\ntiming of dosing, divide dose out for more frequent but smaller doses,\netc.)\n-OR-\n3. For continuation of prior therapy for a seizure disorder\nAuthorization will be issued for 12 months.\nD. Fintepla will be approved based on one of the following:\n1. All of the following:\na. Diagnosis of seizures associated with Dravet syndrome\n-AND-\nb. History of greater than or equal to 8 week trialb of at least two of the following\n(any release formulation qualifies):\n(1) Divalproex (e.g. generic Depakote)\n(2) Levetiracetam (e.g. generic Keppra)\n(3) Topiramate (e.g. generic Topamax)\n(4) Valproic acid (e.g. generic Depakene)\n(5) Zonisamide (generic Zonegran)\n-AND-\nc. One of the following:\n(1) Both of the following:\n(a) Documented history of persisting seizures after titratio",
    "amax)\n(4) Valproic acid (e.g. generic Depakene)\n(5) Zonisamide (generic Zonegran)\n-AND-\nc. One of the following:\n(1) Both of the following:\n(a) Documented history of persisting seizures after titration to the highest\ntolerated dose with each medication trial\n(b) Lack of compliance as a reason for treatment failure has been ruled\nout\n-OR-\n(2) Both of the following:\n© 2025 UnitedHealthcare Services Inc.\n4\n(a) Documentation of failure due to intolerable side effects.\n(b) Reasonable efforts were made to minimize the side effect (e.g. change\ntiming of dosing, divide dose out for more frequent but smaller doses,\netc.)\n-OR-\n2. All of the following:\na. Diagnosis of seizures associated with Lennox-Gastaut syndrome\n-AND-\nb. History of greater than or equal to 8 week trialb of at least two of the following\n(any release formulation qualifies):\n(1) Divalproex (e.g. generic Depakote)\n(2) Lamotrigine (e.g. generic Lamictal)\n(3) Topiramate (e.g. generic Topamax)\n(4) Valproic acid (e.g. generic Depakene)\n-AND-\nc. One of the following:\n(1) Both of the following:\n(a) Documented history of persisting seizures after titration to the highest\ntolerated dose with each medication trial\n(b) Lack of compliance as a reason for treatment failure has been ruled\nout\n-OR-\n(2) Both of the following:\n(a) Documentation of failure due to intolerable side effects.\n(b) Reasonable efforts were made to minimize the side effect (e.g. change\ntiming of dosing, divide dose out for more frequent but smaller doses,\netc.)\n-OR-\n3. For continuation of prior therapy for a seizure disorder\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\n© 2025 UnitedHealthcare Services Inc.\n5\nmanagement programs may apply.\nb For Connecticut, Kentucky and Mississippi business, only a 30 day trial will be required.\n3. Additional Clinical Programs:\n• Notwithstanding ",
    "ealthcare Services Inc.\n5\nmanagement programs may apply.\nb For Connecticut, Kentucky and Mississippi business, only a 30 day trial will be required.\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes\n(ICD-10) and/or claim logic. Use of automated approval and re-approval processes\nvaries by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Anon; Drugs for Epilepsy, Treatment Guidelines from The Medical Letter, 2013; 11:9-19.\n2. Britton JW. Antiepileptic drug withdrawal: literature review. Mayo Clin Proc.\n2002;77(12):1378.\n3. Kwan P, et al. Definition of drug resistant epilepsy; consensus proposal by the ad hoc Task\nForce of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010; 51(6);1069.\n4. Perucca E, et al. The pharmacological treatment of epilepsy in adults. Lancet Neuol 2011;\n10:446-56.\n5. Aptiom [package insert]. Marlborough, MA: Sunovion Pharmaceuticals Inc; March 2019.\n6. Briviact [package insert]. Smyrna, GA: UCB, Inc; May 2023.\n7. Epidiolex [package insert]. Palo Alto, CA: Jazz Pharmaceuticals, Inc; March 2024.\n8. Xcopri [package insert]. Paramus, NJ: SK Life Science, Inc; April 2024.\n9. Fintepla [package insert]. Smyrna, GA: UCB, Inc; December 2023.\n10. Ztalmy [package insert]. Radnor, PA; Marinus Pharmaceuticals, Inc.; April 2024.\nProgram Prior Authorization/Medical Necessity - Single Source Brand\nAnticonvulsants\nChange Control\nDate Change\n2/2014 New program\n5/2014 Addition of Aptiom to program\n11/2014 Updated to clarify trial period for Connecticut and Kentucky to comply\nwith state regulations.\n11/2015 Annual review. Modified criteria to separate out failure due to lack of\nefficacy and adverse events. Changed authorization period. Updated\nreferences.\n6/2016 Updated to include diagnosis criteria and added Briviact. Added\nMaryland requirements. Added Indiana and West Vir",
    "\nefficacy and adverse events. Changed authorization period. Updated\nreferences.\n6/2016 Updated to include diagnosis criteria and added Briviact. Added\nMaryland requirements. Added Indiana and West Virginia coverage\ninformation.\n11/2016 Administrative change. Added California coverage information.\n6/2017 Annual review. References updated. State mandate reference language\nupdated.\n9/2018 Annual review. References updated.\n11/2018 Addition of Epidiolex to program.\n11/2019 Annual review. References updated.\n© 2025 UnitedHealthcare Services Inc.\n6\n7/2020 Addition of Xcopri to program.\n10/2020 Addition of Fintepla to program. Updated Epidiolex criteria to include\nseizures associated with tuberous sclerosis complex.\n10/2021 Updated Vimpat criteria to allow for primary generalized tonic-clonic\nseizures. References updated.\n1/2022 Changed Briviact to require a trial of one generic anticonvulsant prior to\ncoverage.\n5/2022 Updated Fintepla to include Lennox-Gastaut syndrome criteria. Moved\nVimpat to Multi-Source Brand Anticonvulsants criteria due to generic\nlaunch. Updated references. Updated state mandate language.\n10/2022 Added Ztalmy to program.\n11/2022 Removed specific medications for Epidiolex step requirement.\n10/2023 Changed Fycompa to require a trial of one generic anticonvulsant prior\nto coverage.\n10/2024 Annual review. Updated CT/KY/MS state mandate footnote. Updated\nreferences.\n4/2025 Moved Fycompa to Multi-Source Brand Anticonvulsants criteria due to\na generic launch. Aligned trial/failure language for consistency.\n© 2025 UnitedHealthcare Services Inc.\n7"
  ]
}